1. Direct Labor (Surgeons, Nurses, Medical Staff)
Source Primary cost for service delivery in a medical procedure business, implied by 'Cost of services' in transcript and industry benchmarks for medical spas.
Confidence: high
AIRS
T3AirSculpt Technologies, Inc.
Loading chart…
OverviewAirSculpt Technologies, Inc. operates Elite Body Sculpture clinics, specializing in minimally invasive body contouring procedures like AirSculpt for fat removal
AirSculpt Technologies, Inc. operates Elite Body Sculpture clinics, specializing in minimally invasive body contouring procedures like AirSculpt for fat removal and skin tightening. They also offer fat transfer, cellulite smoothing, and have expanded services to include skin excisions, upper blepharoplasty, mastopexy, and AlloClae, increasingly targeting GLP-1 patients. The company sells directly to individual, cash-paying consumers through its single service segment.
Key Inputs And Sourcing
2. AlloClae (Adipose Tissue Allograft)
Source Explicitly mentioned in transcript as having a 'product cost' and impacting gross margin. It is a processed donor adipose matrix.
Confidence: high
3. General Medical Supplies & Consumables
Source Standard single-use items for any medical procedure, such as gloves, sterile wipes, gauze, and needles.
Confidence: high
4. AirSculpt Device Consumables (e.g., cannulas, specialized tips)
Source Specific to the patented AirSculpt technology and specialized device used for fat removal and sculpting.
Confidence: medium
5. Local Anesthetics
Source AirSculpt procedures are performed under local anesthesia, incurring a direct drug cost.
Confidence: high
Industry Publications
- Aesthetic Surgery Journal (aestheticsurgeryjournal.com) — Provides clinical advancements, research, and peer-reviewed articles on plastic and aesthetic surgery, including body contouring, directly relevant to AirSculpt's procedures.
- Plastic and Reconstructive Surgery (journals.lww.com/plasreconsurg) — The official medical journal of the American Society of Plastic Surgeons, offering comprehensive coverage of surgical techniques and innovations in body contouring.
- Modern Aesthetics (modernaesthetics.com) — Focuses on current approaches to patient management, minimally invasive treatments, and new technologies in aesthetic medicine, aligning with AirSculpt's service offerings.
- MedEsthetics Magazine (medestheticsmag.com) — A business resource for practitioners in noninvasive and minimally invasive medical aesthetic procedures, covering industry news, trends, and practice management relevant to AirSculpt's clinic operations.
- Aesthetics Journal (aestheticsjournal.com) — Offers a mix of clinical content, business insights, and real-time industry news for non-surgical aesthetics, crucial for monitoring market trends and competitive landscape.
Economic Data Watch
1. FRED (Federal Reserve Economic Data) — Retail Sales
Metric/field Retail Sales: Nonstore Retailers (NAICS 454) (Series ID: RSNSR)
Cadence monthly
Why it matters Indicates consumer discretionary spending on non-essential goods and services, which directly impacts demand for elective aesthetic procedures.
Signal to watch Sustained increase signals stronger consumer demand; sustained decrease signals weakening demand.
Confidence: high
2. The Conference Board — Consumer Confidence Index
Metric/field Consumer Confidence Index (CCI)
Cadence monthly
Why it matters A leading indicator of consumer spending and economic health, directly influencing willingness to spend on elective procedures.
Signal to watch Rising index suggests increasing consumer optimism and potential for higher discretionary spending; falling index suggests pessimism.
Confidence: high
3. FRED (Federal Reserve Economic Data) — Personal Income and Outlays
Metric/field Disposable Personal Income (DPI) (Series ID: DPI)
Cadence monthly
Why it matters Measures the income available to households for spending and saving after taxes, directly impacting their capacity for elective procedures.
Signal to watch Growth in DPI supports higher discretionary spending; decline indicates tighter consumer budgets.
Confidence: high
4. FRED (Federal Reserve Economic Data) — Consumer Credit
Metric/field Consumer Credit Outstanding (TOTALSL) (Series ID: TOTALSL)
Cadence monthly
Why it matters AIRS mentions financing dependence. Changes in consumer credit availability and utilization can impact customers' ability to finance procedures.
Signal to watch Increasing consumer credit availability and utilization (with stable delinquency rates) could support procedure financing; tightening credit could be a headwind.
Confidence: medium
5. BLS (Bureau of Labor Statistics) — Employment Situation
Metric/field Unemployment Rate (UNRATE) (Series ID: UNRATE)
Cadence monthly
Why it matters A strong labor market generally correlates with higher consumer confidence and disposable income, supporting demand for elective services.
Signal to watch Decreasing unemployment rate suggests a robust economy and potentially higher discretionary spending; increasing rate suggests economic weakness.
Confidence: high
Free Alt Data Watch
1. Google Trends — Search Interest
Metric/field Search volume for 'AirSculpt' (relative search interest score)
Cadence weekly
Why it matters Direct indicator of consumer interest and brand awareness for AIRS's core services.
Signal to watch Sustained increase in search volume indicates growing interest and lead generation; sustained decrease suggests fading interest.
Confidence: high
2. Google Trends — Search Interest
Metric/field Search volume for 'skin tightening after GLP-1' (relative search interest score)
Cadence weekly
Why it matters Tracks interest in a key GLP-1 adjacent service that AIRS is actively expanding, indicating the potential market for new procedures.
Signal to watch Increasing search volume suggests growing demand for GLP-1 related aesthetic solutions, a bullish signal for AIRS's strategy.
Confidence: high
3. Google Trends — Search Interest
Metric/field Search volume for 'Ozempic' OR 'Wegovy' OR 'Mounjaro' OR 'Zepbound' (combined relative search interest score)
Cadence weekly
Why it matters Indicates the overall adoption and public interest in GLP-1 drugs, which drives the underlying patient pool for AIRS's GLP-1 related procedures.
Signal to watch Sustained high or increasing search volume for GLP-1 drugs suggests a growing potential market for AIRS.
Confidence: high
4. Reddit (r/PlasticSurgery) — Subreddit Activity
Metric/field Number of posts/comments mentioning 'GLP-1' OR 'Ozempic face' OR 'skin laxity' OR 'body contouring'
Cadence daily
Why it matters Provides qualitative insights into patient concerns, discussions, and emerging trends related to post-GLP-1 aesthetic needs and procedures.
Signal to watch Increased discussion around GLP-1 related aesthetic issues suggests growing patient awareness and potential demand for solutions.
Confidence: medium
5. Reddit (r/Ozempic) — Subreddit Activity
Metric/field Number of posts/comments mentioning 'skin tightening' OR 'plastic surgery' OR 'body contouring' OR 'fat transfer' OR 'AlloClae'
Cadence daily
Why it matters Direct feedback and discussions from GLP-1 users about their aesthetic concerns and interest in procedures, offering early signals of demand.
Signal to watch Increased mentions of aesthetic procedures by GLP-1 users indicates a direct need that AIRS can address.
Confidence: medium
Paid Alt Data Watch
1. IQVIA — GLP-1 Prescription Data
Metric/field Total weekly/monthly prescription volume for GLP-1 agonists (Ozempic, Wegovy, Mounjaro, Zepbound)
Cadence monthly
Why it matters Direct measure of the growth and adoption of GLP-1 drugs, which is a foundational driver for AIRS's GLP-1 patient strategy.
Signal to watch Sustained growth in GLP-1 prescription volumes indicates an expanding target market for AIRS.
Confidence: high
2. M Science — Aesthetic Treatment Volume Tracker
Metric/field Quarterly volume trends for 'skin tightening procedures' and 'body contouring procedures' across the aesthetic market
Cadence quarterly
Why it matters Provides granular, market-wide data on the specific types of procedures AIRS offers, including those targeting GLP-1 patients.
Signal to watch Positive growth in these procedure categories suggests a healthy market and validates AIRS's strategic focus.
Confidence: high
3. Facteus / Earnest Research (Credit Card Data) — Consumer Spending Data
Metric/field Monthly aggregate spending on 'elective aesthetic procedures' or 'medspa services' (transaction volume and average ticket size)
Cadence monthly
Why it matters Direct measure of actual consumer spending on the broader aesthetic market, indicating overall demand and pricing trends.
Signal to watch Increasing spending and stable average ticket size suggest strong consumer demand for aesthetic services.
Confidence: high
4. SimilarWeb — Website Analytics
Metric/field Airsculpt.com: Monthly unique visitors, bounce rate, and average session duration
Cadence monthly
Why it matters Tracks the effectiveness of AIRS's digital marketing and online customer acquisition efforts, crucial for a direct-to-consumer model.
Signal to watch Increasing unique visitors, decreasing bounce rate, and increasing session duration indicate improved online engagement and lead quality.
Confidence: high
5. Placer.ai — Foot Traffic Analytics
Metric/field Monthly foot traffic to 'Elite Body Sculpture' centers (total visits and average visit duration)
Cadence monthly
Why it matters Provides a real-time, physical indicator of customer interest and visits to AIRS's locations, complementing online data.
Signal to watch Increasing foot traffic suggests growing in-person interest and potential for higher case volumes.
Confidence: medium
Search Keywords Brand Product
- AirSculpt
- AirSculpt+
- AirSculpt Smooth
- Power BBL
- Up a Cup
- Hip Flip
- AlloClae
- skin excision
- upper blepharoplasty
- mastopexy
- body contouring
- fat removal
- fat transfer
- skin tightening
- cellulite removal
- minimally invasive surgery
- GLP-1 weight loss aesthetics
- aesthetic procedures
- medical aesthetics
Search Keywords Event Phrases
- AirSculpt earnings
- AirSculpt Q2 2026
- AlloClae partnership
Search Keywords Policy Regulatory
- GLP-1 insurance coverage
- aesthetic procedure financing
- What They Do (Plain English & Analogies)
- AirSculpt Technologies, Inc. (AIRS) is like a specialized body sculptor for people who want to remove unwanted fat and tighten their skin without undergoing traditional, more invasive surgery. They use a unique, minimally invasive technique called AirSculpt to precisely remove fat cells and sculpt targeted areas of the body, almost like a highly precise vacuum cleaner for fat, while the patient is awake. They also offer procedures to transfer a patient's own fat to other areas, like enhancing breasts or buttocks, and treatments for cellulite and skin tightening. Essentially, they help people achieve their desired body shape with less downtime and discomfort than older methods.
- Very Brief History
- AirSculpt Technologies, Inc. was founded in 2012 and is headquartered in Miami Beach, Florida. The company has evolved to become a fast-growing national provider of body contouring procedures, operating under the brand Elite Body Sculpture.
- "Street Stereotype"
- The company is generally perceived by investors and analysts as a business that is stabilizing after a challenging period. The 'street' is focused on whether AirSculpt can convert its record lead and consultation volumes into higher case counts, effectively manage its customer acquisition costs, and prove that its new GLP-1-linked procedures can significantly expand its market and drive sustained profitable growth. There's a cautious optimism about its turnaround potential, especially given the dynamic consumer environment.
- Subsidiaries On Linked In*
- Elite Body Sculpture — Operating brand and primary clinic name for AirSculpt Technologies, Inc.; LinkedIn: elite-body-sculpture
- Customer Sectors & Example Clients
- AirSculpt's customers are individual, cash-pay consumers seeking elective aesthetic medical procedures. They operate in the medical aesthetics and wellness sectors. Since they serve individual consumers directly, there are no specific top corporate clients.
- New Customers / Segments They'Re Targeting
- AirSculpt is actively targeting patients using GLP-1 weight-loss drugs. These patients often experience changes in their body and face, leading to new aesthetic needs such as skin tightening, skin removal, and volume restoration. The company is expanding its portfolio of procedures, including skin excision, upper blepharoplasty, mastopexy, and AlloClae (for targeted volume restoration), specifically to cater to the evolving aesthetic needs of GLP-1 patients and those without enough fat for traditional fat transfer.
- Sales Geographies And Expansion Plans
- The company currently operates centers in the United States, Canada, and the United Kingdom. Management has indicated plans to expand its geographic footprint and center base over time as its balance sheet and cash flow generation strengthen, but no specific new geographies have been disclosed.
- How Key Themes May Help/Hurt
- The 'GLP-1 Long '24: Improved Looks' theme is a significant tailwind for AirSculpt. The increased usage of GLP-1 drugs is driving demand for cosmetic surgeries, skin tightening, and related aesthetic products as individuals seek to address changes in appearance post-weight loss. AirSculpt is directly capitalizing on this by introducing new services like skin excision and AlloClae, which are highly relevant to GLP-1 patients. This theme helps by expanding AirSculpt's addressable market and creating a new, structural demand driver for their services. However, potential long-term side effects, health risks, or negative public perception associated with prolonged GLP-1 usage could lead to a decline in drug popularity, subsequently impacting related industries that benefit from the 'improved looks' trend. While AirSculpt has not seen a noticeable impact from employers dropping GLP-1 coverage, a broader moderation in GLP-1 uptake could also hurt the company's growth strategy.
3 Main Long-Term Bull Details
- Expanding Addressable Market via GLP-1 Patients: AirSculpt is strategically introducing new procedures like skin excision, upper blepharoplasty, mastopexy, and AlloClae to cater to the significant and growing market opportunity presented by GLP-1 patients, which is expected to represent a $100 million-plus long-term revenue opportunity.
- Stabilization and Case Volume Growth: The company has achieved two consecutive quarters of stable revenue and positive underlying case volume growth, indicating a successful turnaround and improved operational performance, which is a significant shift from previous declines.
- Financial Flexibility for Future Expansion: AirSculpt has strengthened its balance sheet, reduced gross debt, and increased cash, providing the financial flexibility to support future growth, including potential de novo expansion of its geographic footprint and center base over time.
3 Main Long-Term Bear Details
- Macroeconomic Sensitivity and Consumer Discretionary Spending: The company operates in a discretionary consumer spending environment, which remains sensitive to macroeconomic fluctuations, leading to 'choppy consumer environment' and moderating sales trends, impacting revenue visibility.
- Elevated Customer Acquisition Costs and Marketing Optimization: Customer acquisition costs are currently elevated due to intentional brand marketing investments, and while expected to improve, the efficiency and ROI of these investments need to be fully optimized to drive profitable growth.
- Early Stage of New Offerings: The new procedures and marketing initiatives, particularly those targeting GLP-1 patients, are still in early stages of implementation, and their ability to consistently drive sustained growth and offset potential declines in traditional procedures requires further proof and execution.
- Competitors And Differentiation
- While the transcript does not name direct competitors, in the broader elective aesthetics market, companies like InMode, Cutera, and AbbVie (with CoolSculpting) offer various body contouring and skin tightening solutions. AirSculpt differentiates itself through its proprietary, minimally invasive AirSculpt® technique, which removes fat cell by cell under local anesthesia through small openings, emphasizing precision, quick recovery times, and simultaneous skin tightening. They aim to provide a premium consumer experience and are expanding their specialized procedure portfolio to meet evolving patient needs, particularly those related to GLP-1 weight loss.
- Recent Performance & What The Market'S Focused On
- In the second quarter of fiscal 2026, AirSculpt reported revenue of $42.9 million, a decrease of 2.5% year-over-year. On a same-center basis (excluding London), revenue declined approximately 1%, reflecting positive 1% case growth, marking the second consecutive quarter of year-over-year case growth, a sign of stabilization. Adjusted EBITDA was $4.9 million, roughly 11.5% of revenue. The company reaffirmed its revenue guidance at the lower end and updated its adjusted EBITDA outlook to a range of $12 million to $14 million, reflecting increased marketing investments. The market is focused on the company's ability to convert lead and consultation volumes into higher case counts, the efficiency of its marketing spend, and the traction and economic impact of its new GLP-1-linked procedures, particularly AlloClae, as well as sustained same-center sales growth.
- Revenue Segments And Estimated Mix
- Direct Medical Procedure Services — Mix: 100%; Source: Existing text tables and transcript imply this remains the sole segment, with new procedures contributing to this overall category.; Trend: Stable revenue for two consecutive quarters, with positive underlying case volume growth.
- Product Brands
- AirSculpt
- AirSculpt+
- AirSculpt Smooth
- Power BBL
- Up a Cup
- Hip Flip
- AlloClae
Bull / Bear DetailsAirSculpt (AIRS) is stabilizing with two consecutive quarters of stable revenue and positive case growth, driven by an expanded portfolio of GLP-1-linked aesthe
Thesis
AirSculpt (AIRS) is stabilizing with two consecutive quarters of stable revenue and positive case growth, driven by an expanded portfolio of GLP-1-linked aesthetic procedures and a strengthened balance sheet. Despite a choppy consumer environment and elevated customer acquisition costs, strategic marketing investments and new offerings like AlloClae position the company for sustained profitable growth and market expansion into 2027. (Updated: 2026-09-07)
Bull case
AirSculpt has achieved two consecutive quarters of stable revenue and positive same-center case growth, signaling a successful business stabilization and turnaround. This underlying momentum, combined with strategic investments in marketing and new procedures, positions the company for year-over-year revenue and Adjusted EBITDA growth in Q4 2026, despite a dynamic consumer environment.
The company is aggressively expanding its portfolio of GLP-1-linked aesthetic procedures, including skin excisions, upper blepharoplasty, mastopexy, and the new AlloClae partnership. These new services address the evolving needs of GLP-1 patients, represent a significant long-term revenue opportunity exceeding $100 million, and broaden AirSculpt's addressable market.
AirSculpt has significantly strengthened its financial position, reducing gross debt by over $30 million since early 2025 and increasing cash by over $10 million. The recent extension of its credit facility maturity to November 2027 and multiple refinancing term sheets provide ample liquidity and flexibility to support future growth initiatives and de novo expansion.
Bear case
Despite overall stabilization, the company experienced moderating sales trends in June and July, attributing it to a "choppy consumer environment." This indicates continued fragility in discretionary consumer spending, leading to a projected single-digit revenue decline in Q3 2026 and ongoing near-term revenue visibility challenges.
Customer acquisition costs (CAC) increased to approximately $3,500 per case in Q2 2026, up from $2,900 in the prior year, reflecting elevated marketing investments that are not yet fully optimized. This higher CAC, coupled with headwinds from the evolving AI search landscape, could pressure margins and marketing efficiency in the short term.
While new procedures like AlloClae are promising, they are in early stages of implementation and are not yet contributing to current guidance, implying a delayed impact on financial results. The success of these offerings and the ability to efficiently market them to GLP-1 patients still require further proof and execution.
Bull / Bear Case
- Bear Case
- Despite signs of stabilization, AirSculpt faces significant headwinds from a "choppy consumer environment," which led to moderating sales trends in June and July and a projected single-digit revenue decline for Q3 2026. This indicates continued fragility in discretionary consumer spending and ongoing near-term revenue visibility challenges. Customer acquisition costs (CAC) remain elevated at approximately $3,500 per case, up from $2,900 in the prior year, reflecting marketing investments that are not yet fully optimized and potentially pressuring margins. Additionally, the evolving AI search landscape is creating headwinds for click-through rates, further impacting marketing efficiency. While new procedures like AlloClae are promising, they are in early stages and not yet contributing to current guidance, implying a delayed impact on financial results and requiring further proof of successful execution.
- Bull Case
- AirSculpt Technologies is demonstrating a turnaround, achieving two consecutive quarters of stable revenue and positive same-center case growth, indicating business stabilization. The company is strategically expanding its addressable market by introducing new GLP-1-linked aesthetic procedures, such as skin excisions, upper blepharoplasty, mastopexy, and the AlloClae partnership, which are expected to unlock a long-term revenue opportunity exceeding $100 million. Furthermore, AirSculpt has strengthened its financial position, reducing gross debt by over $30 million since early 2025 and increasing cash by over $10 million. This provides crucial liquidity and flexibility for future growth initiatives and potential de novo expansion. Management anticipates year-over-year revenue and Adjusted EBITDA growth in Q4 2026, driven by these strategic investments.
- More Compelling & Why
- Bear. The stock's significant underperformance since the earnings call, with a -35.13% return post-earnings compared to SPY's -0.07%, strongly indicates bearish sentiment. This is anchored by a high EV/EBITDA ratio of approximately 33.12x and a P/S ratio of 1.3x, which is considered expensive compared to its estimated fair value, suggesting the current valuation does not adequately account for the "choppy consumer environment" and expected Q3 revenue decline. The strongest argument for the bear case is the continued fragility in discretionary consumer spending, evidenced by moderating sales trends and projected Q3 revenue decline, coupled with elevated customer acquisition costs and the market's negative reaction. My view would flip to bullish if the company demonstrates consistent positive same-center sales growth in Q3 (not just Q4), a clear and sustained reduction in customer acquisition costs, and tangible revenue contribution from its new GLP-1-linked procedures.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Customer Acquisition Cost (CAC) and Marketing Efficiency | Elevated CAC directly impacts profitability. Management's ability to optimize marketing spend and reduce CAC is crucial for margin expansion and long-term shareholder value, especially with increased marketing investments. | Customer acquisition cost per case (Q2 2026 was ~$3,500). Marketing spend as a percentage of revenue (YTD 2026 was ~20%). | CAC decreases below $3,500 or marketing spend as % of revenue declines towards 18% = bullish. CAC remains elevated or increases, or marketing spend as % of revenue increases = bearish. | Company earnings releases and conference calls (Q3 2026 earnings expected in November 2026, Q4 2026 earnings expected in February 2027). | SimilarWeb: AirSculpt.com web traffic, conversion rates | |
| Debt Refinancing Progress and Liquidity | Strengthening the balance sheet and securing long-term financing provides essential financial flexibility for future growth, including potential de novo expansion, and reduces financial risk. | Updates on refinancing discussions, new term sheets, and the finalization of a new credit facility. Total liquidity ($24M at Q2 2026 end, including $19M cash and $5M revolver). | Announcement of a successful refinancing with favorable terms (e.g., lower interest rate, extended maturity beyond November 2027) = bullish. Delays in refinancing or less favorable terms = bearish. | Company press releases, SEC filings (10-Q, 8-K), and earnings conference calls. | ||
| Achievement of Updated Full-Year Guidance | Meeting or exceeding guidance demonstrates management's ability to execute on strategic priorities and navigate a dynamic consumer environment, which is essential for building and maintaining investor confidence. | Full-year 2026 revenue guidance ($160M-$170M, lower end reaffirmed) and Adjusted EBITDA guidance ($12M-$14M). | Reporting full-year revenue at or above the lower end of guidance ($160M) and Adjusted EBITDA within or above the $12M-$14M range = bullish. Missing either range = bearish. | Company earnings releases and conference calls (Q4 2026 earnings expected in February 2027). | ||
| Same-Center Sales Growth | This is a direct indicator of business stabilization and underlying demand. Management's near-term focus is increasing same-center sales, which is crucial for future profitability and growth. | Comparable same-center revenue change year-over-year for Q3 and Q4 2026, and commentary on trends in July/August 2026. | Q3 comparable revenue down single digits (e.g., -1% to -9%) or better = bullish (in line with guidance). Q4 comparable revenue growth = bullish. Q3 decline steeper than single digits or Q4 no growth = bearish. | Company earnings releases and conference calls (Q3 2026 earnings expected in November 2026, Q4 2026 earnings expected in February 2027). | M Science: Aesthetic Treatment Volume Tracker (for body contouring trends) | |
| Rollout and Adoption of New GLP-1-Linked Procedures (AlloClae, Skin Excisions, etc.) | These new procedures expand the addressable market, increase center productivity, and are expected to be a significant long-term revenue opportunity ($100M+) by catering to GLP-1 patients' evolving aesthetic needs. | Number of centers offering AlloClae (rolling out later this quarter), skin excisions (currently ~20/31), upper blepharoplasty, and mastopexy. Commentary on attach rates or revenue contribution from these new procedures. | AlloClae rollout to more centers than initial pilot or explicit positive commentary on early adoption/revenue contribution = bullish. No update or slow rollout/weak adoption = bearish. | Company earnings releases and conference calls (Q3 2026 earnings expected in November 2026, Q4 2026 earnings expected in February 2027). | Google Trends: 'AlloClae reviews,' 'AirSculpt skin excision,' 'GLP-1 skin tightening.' Reddit: r/PlasticSurgery, r/Ozempic for patient discussions. | M Science: Aesthetic Treatment Volume Tracker (for specific procedure volumes) |
Key Reported Metrics, Reratings Triggers & ResultsThis metric is a direct signal of consumer conversion and utilization across centers, leading to revenue inflection and margin leverage.
Upcoming print · 2026-11-09
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| Case Volume (Procedures Performed) | +1% | This metric is a direct signal of consumer conversion and utilization across centers, leading to revenue inflection and margin leverage. |
| Same-Center Revenue Growth | -1% | This metric is a key indicator of the underlying health and stabilization of mature clinics and a primary focus for management to drive sustained profitable growth. |
| Total Revenue | -2.5% | This is the core measure of demand and pricing, reflecting whether strategic initiatives and marketing efforts are converting into booked procedures and overall business health. |
Key QuestionsCan AirSculpt convert the recent stabilization and positive case growth into sustained same-center revenue growth in Q4, especially given the moderating sales t
Can AirSculpt convert the recent stabilization and positive case growth into sustained same-center revenue growth in Q4, especially given the moderating sales trends seen in June and July and the expected single-digit decline in Q3?
- Question 2
Will the expanded portfolio of GLP-1-linked procedures, including skin excisions, upper blepharoplasty, mastopexy, and the new AlloClae offering, gain measurable traction and begin to contribute meaningfully to revenue and addressable market expansion in the coming quarters, especially as they are currently excluded from guidance?
- Question 3
Can AirSculpt's increased marketing investments lead to improved efficiency and a reduction in customer acquisition costs, ultimately driving Adjusted EBITDA within or above the updated guidance range of $12 million to $14 million for the full year, despite the current elevated CAC?
Earnings Transcript Summary
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. Introducing new services to capture the GLP-1 market opportunity: Management is expanding its portfolio of procedures (e.g., skin excision, upper blepharoplasty, mastopexy, AlloClae partnership) to serve the evolving aesthetic needs of GLP-1 patients, which they see as a significant long-term growth driver. 2. Enhancing sales and marketing strategy: The company is refining its marketing through a "test and learn" approach to optimize reach for GLP-1 patients and new procedures, aiming for higher ROI and marketing efficiency. They are also training sales teams and implementing optimization tools. 3. Maintaining strong financial discipline: This includes strengthening the balance sheet, raising capital through an ATM program, and managing debt, providing flexibility for future growth and de novo expansion. | Call Takeaway & ToneThe overall takeaway is that AirSculpt Technologies is making "meaningful progress on its transformation" and is stabilizing its business in a "dynamic consumer environment." The tone was cautious but confident. Management highlighted stable revenue, positive same-center case growth, and strategic investments in new GLP-1 related procedures and marketing as key drivers. They acknowledged moderating sales trends in June and July but reaffirmed their full-year guidance (at the lower end) and expect improved performance in the second half due to ongoing initiatives. The company is focused on converting stabilization into sustained profitable growth, emphasizing same-center sales, marketing efficiency, and consistent execution. | Prior Quarter'S Y/Y Growth By SegmentTotal Revenue (Q1 2026): Flat (0%) year-over-year. Same-center revenue (Q1 2026): +1% year-over-year. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. Market environment and consumer trends (July/August) and ability to sustain procedure volume growth: Management acknowledged softening trends in June that continued into July, attributing it to a "choppy consumer environment." They expressed confidence that new services, marketing, and disciplined execution would lead to growth by year-end, reaffirming the lower end of revenue guidance. 2. Strategic rationale of the AlloClae partnership and the long-term vision for AirSculpt as a full-service aesthetics platform: Management explained AlloClae as a complementary procedure that expands reach to patients without enough fat for traditional transfer, fitting within their body contouring brand. They confirmed a constant evaluation of procedures to increase center productivity and drive same-store sales, aiming to expand offerings that make sense for patients. 3. Evidence of higher ROI from increased marketing spend and the evolution of marketing strategy (including CAC and AI search landscape): Management stated they monitor ROI by assessing if investments generate more profit over time. They pointed to two consecutive quarters of stable revenue and case growth as evidence of the enhanced marketing strategy's effectiveness. They are using a "test and learn" approach for GLP-1 patients and new procedures, expecting marketing to become more efficient. Regarding AI search, they are investing in how they appear in search engines and LLMs, and also focusing on non-AI channels like ratings and reviews. | Revenue SegmentsTotal Revenue: -2.5% year-over-year. Same-center revenue (excluding London): -1% year-over-year. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketAirSculpt Technologies is broadening its consumer reach to capture the growing opportunity presented by GLP-1 patients and is expediting the expansion of its portfolio of procedures to serve their evolving aesthetic needs. The company completed over 200 skin excision procedures and expanded the offering to additional centers, also broadening services to include upper blepharoplasty and mastopexy. These new procedures further expand the addressable market and increase center productivity, while allowing AirSculpt to better serve patient needs. The company expects this to represent a $100 million-plus long-term revenue opportunity across its existing base of centers, with increasing long-term potential as de novos resume. AirSculpt also announced a partnership with Tiger Aesthetics to offer AlloClae, a structural adipose tissue allograft for non-surgical body contouring, which will start rolling into centers later this quarter. This partnership allows AirSculpt to reach patients previously unserved, including those without enough fat for traditional fat transfer, and addresses growing consumer interest as GLP-1 use creates a need for targeted volume restoration. The company has additional core body contouring procedures in the pipeline and is constantly evaluating new solutions based on patient needs. Skin removal or excisions are currently available in approximately 20 out of 31 locations. | About CompetitionThe transcript does not contain explicit mentions of competition or competitive dynamics. | About The Broader IndustryThe company noted moderating sales trends in June, which it attributes to executing a transformation in a dynamic and choppy consumer environment. AirSculpt's guidance assumes a stable macroeconomic environment through the balance of the year and does not contemplate any further deterioration in consumer demand. The company also acknowledged that the AI search landscape is creating headwinds for click-through rates on Google. | Where Things Are HeadedAirSculpt's near-term focus remains squarely on increasing same-center sales. Longer term, the company believes there is meaningful growth in new procedures and de novo expansion, intending to expand its geographic footprint and center base as its balance sheet and cash flow generation strengthen. AirSculpt expects the actions underway to be reflected in its results in the quarters ahead. The company reaffirmed its outlook at the lower end of its revenue guidance and updated its adjusted EBITDA outlook to a range of $12 million to $14 million, reflecting an intentional investment of an additional $5 million in marketing this year to support future growth. AirSculpt expects third-quarter revenue to be down single digits on a comparable basis, but anticipates continued ramp of existing and new service offerings and market efforts to deliver year-over-year growth in revenue and adjusted EBITDA on a comparable basis in Q4. The guidance does not include any contributions from new offerings like AlloClae, given their early stage of implementation. The company believes its investments position the business well for improving performance through the remainder of the year, focusing on disciplined execution, maintaining financial flexibility, and continuing to invest in initiatives to drive long-term shareholder value. | Updates On ThemeImproved | Broader Themes EmergingThe impact of AI search landscapes (e.g., Google, OpenAI, Claude) on direct-to-consumer marketing, creating headwinds for click-through rates, is an emerging broader theme. | Bullish-Leaning Quotes (Short)Our addressable market is larger, our procedure mix is broader, and our operating platform is more disciplined than it was 12 months ago. We remain confident in the opportunities ahead and our ability to deliver long-term shareholder value. The business is much stronger on almost all accounts compared to a year ago. GLP-1 continues to represent a significant long-term growth driver for AirSculpt, with nearly 19 million potential patients interested in body contouring or related aesthetic procedures over time. Underlying case volume increased year-over-year. | Bearish-Leaning Quotes (Short)Center sales began the quarter positively and saw moderating sales trends in June, which we attribute to a dynamic consumer environment. Revenue for the quarter was $42.9 million, a decrease of 2.5% versus the prior year quarter. Customer acquisition cost for the quarter was roughly $3,500 per case, compared to approximately $2,900 in the prior year quarter. While elevated... Adjusted EBITDA was $4.9 million, roughly 11.5% of revenue, a decrease of $900,000 from the prior year. We expect third quarter revenue to be down single digits. AI search overviews creating headwinds as far as clicks are concerned. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2025-08-01 | Q2 showed stabilizing trends: revenue $44M (-13.7% YoY) with record leads, steady ARPC, and improving EBITDA margin (13.3%). Management reiterated FY25 guidance ($160–170M rev, $16–18M EBITDA) as marketing efficiency, financing expansion, and a GLP-1-linked skin-tightening pilot gain traction. Consumer hesitancy and 22% same-store decline weighed on sentiment, yielding a muted (~3%) stock reaction. | Earnings Transcript | Mixed | -10.51% (vs SPY: -10.37%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| AIRS_c990eec4 | later this quarter | 2026-08-11 | 2026-09-30 | Initial rollout and patient treatment with AlloClae in select centers, a structural adipose tissue allograft for non-surgical body contouring. | This partnership expands AirSculpt's addressable market by serving patients without enough fat for traditional transfers and capitalizes on growing interest in targeted volume restoration, particularly among GLP-1 users, with expected accretive gross margin dollars. | Ticker | 2026-08-10 | earnings_transcript |